Sign in

ALKS on Nasdaq

Alkermes

Irish-domiciled healthcare company

Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc.3 Its shares trade on Nasdaq under the symbol ALKS.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with PHIBRO ANIMAL HEALTH CORP, PTC Therapeutics or Indivior, or pick any stock.

  • TickerALKS on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersDublin1
  • Websitewww.alkermes.com
  • Legal formBusiness Corporation4
  • LEI549300YHRMYLL071E2434
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O CT Corporation System, 17101 Harrisburg, United States4
  • Registered withPennsylvania Department of State, 9682814

See how the biggest companies compare on our leaderboards

Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

17.2%Operating margin7
16.4%Net margin7
-5.2%Revenue growth, 20257
13.3%Return on equity7
$480.3MFree cash flow7

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Vivitrol brought in 32% of the revenue Alkermes broke down this way in fiscal 2025.

  1. Vivitrol$467.9M732%up 2% from 2024
  2. Aristada And Aristada Initio$370.0M725%up 7% from 2024
  3. Lybalvi$346.7M723%up 24% from 2024
  4. Royalty$245.3M717%down 31% from 2024
  5. Manufacturing Revenue$46.0M73%down 61% from 2024
Products and services by year
Products and services202320242025
Vivitrol$400.4M$457.3M$467.9M
Aristada And Aristada Initio$327.7M$346.2M$370.0M
Lybalvi$191.9M$280.0M$346.7M
Royalty$600.9M$354.7M$245.3M
Manufacturing Revenue$142.5M$119.4M$46.0M

Regions

United States brought in 93% of the revenue Alkermes broke down this way in fiscal 2025.

  1. United States$1.4B793%down 3% from 2024
  2. Foreign Country Excluding Specified Country$102.4M77%down 30% from 2024
  3. I E$754.0K70%down 42% from 2024
Regions by year
Regions202320242025
United States$1.5B$1.4B$1.4B
Foreign Country Excluding Specified Country$170.3M$146.2M$102.4M
I E$1.2M$1.3M$754.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue13¢$196.5M
  • Research and development21¢$324.0M
  • Selling, general and admin46¢$701.5M
  • Income tax3¢$49.8M
  • Profit16¢$241.7M

Out of $1.5B in revenue.7

Where each dollar of operating cash went, fiscal 2025

  • Capital spending8¢$40.4M
  • Kept or used elsewhere92¢$480.3M

Out of $520.8M of cash from operations.7

Financial statements

Revenue8910117$1.5B in 2025+26% since 2019
0$500.0M$1.0B$1.5B$2.0B2019: $1.2B$1.2B20192020: $1.0B$1.0B2020−11%2021: $1.2B$1.2B2021+13%2022: $1.1B$1.1B2022−5%2023: $1.7B$1.7B2023+50%2024: $1.6B$1.6B2024−6%2025: $1.5B$1.5B2025−5%
Operating income8910117$254.0M in 2025
-$200.0M0$200.0M$400.0M$600.0M2019: -$175.5M-$175.5M20192020: -$112.4M-$112.4M2020−36%2021: $97.7M$97.7M20212022: -$6.1M-$6.1M20222023: $414.1M$414.1M20232024: $420.6M$420.6M2024+2%2025: $254.0M$254.0M2025−40%
Net income8910117$241.7M in 2025
-$200.0M0$200.0M$400.0M2019: -$196.6M-$196.6M20192020: -$110.9M-$110.9M2020−44%2021: -$48.2M-$48.2M2021−57%2022: -$158.3M-$158.3M2022+229%2023: $355.8M$355.8M20232024: $367.1M$367.1M2024+3%2025: $241.7M$241.7M2025−34%

Every line of the income statement as filed: the last 3 fiscal years, latest first.7

Period ending2025-12-312024-12-312023-12-31
Total revenues$1.5B$1.6B$1.7B
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)$196.5M$245.3M$253.0M
Research and development$324.0M$245.3M$270.8M
Selling, general and administrative$701.5M$645.2M$689.8M
Amortization of acquired intangible assets$1.1M$35.7M
Total expenses$1.2B$1.1B$1.2B
OPERATING INCOME FROM CONTINUING OPERATIONS$254.0M$420.6M$414.1M
Interest income$45.3M$42.5M$30.9M
Interest expense-$12.3M-$22.6M-$23.0M
Other income (expense), net$4.5M$3.2M-$425.0K
Total other income, net$37.5M$23.1M$7.4M
INCOME BEFORE INCOME TAXES$291.4M$443.8M$421.5M
INCOME TAX PROVISION (BENEFIT)$49.8M$71.6M-$97.6M
NET INCOME FROM CONTINUING OPERATIONS$241.7M$372.1M$519.2M
LOSS FROM DISCONTINUED OPERATIONS, NET OF TAX-$5.1M-$163.4M
NET INCOME$241.7M$367.1M$355.8M
Earnings per ordinary share from continuing operations - basic$1$2$3
Loss per ordinary share from discontinued operations - basic-$0-$1
Earnings per ordinary share - basic$1.47$2.22$2.14
Earnings per ordinary share from continuing operations - diluted$1$2$3
Loss per ordinary share from discontinued operations - diluted-$0-$1
Earnings per ordinary share - diluted$1.43$2.17$2.10
Basic164.7M shares165.4M shares166.2M shares
Diluted168.7M shares169.2M shares169.7M shares
Holding (loss) gain, net of a tax (benefit) provision of $(55), $292, and $1,195, respectively-$133.0K$1.1M$7.8M
COMPREHENSIVE INCOME$241.5M$368.2M$363.5M
Tax provision (benefit)-$55.0K$292.0K$1.2M

Compare Alkermes with another company

Corporate structure

Alkermes sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Alkermes

  • Alkermes Waltham, Massachusetts, United States
    • Alkermes (United States) Subsidiary · United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Alkermes reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$95.0M15 Mar 31, 2011$96.9M15 Mar 31, 2010−1.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$38.4M15 Mar 31, 2011$79.3M15 Mar 31, 2010−51.6%
Marketable securities, current$162.9M15 Mar 31, 2011$202.1M15 Mar 31, 2010−19.4%
Marketable securities, non-current$93.4M15 Mar 31, 2011$68.8M15 Mar 31, 2010+35.7%

Inventory

ItemLatestA year beforeChange
Inventory, total$20.4M15 Mar 31, 2011$20.7M15 Mar 31, 2010−1.1%

Leadership

Who has led Alkermes, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Richard F. Pops2006–2011
  2. David A. Broecker2007–2009
  3. Richard F. Pops2011–2026
  4. Blair Curtis Jackson2026–now

President

  1. David A. Broecker2007–2009
  2. Richard F. Pops2009–2011
  3. Shane Cooke2011–2018
  4. Blair Curtis Jackson2026–now

Chief financial officer

  1. James M. Frates2006–2011
  2. James M. Frates2011–2020
  3. Iain Michael Brown2021–2025
  4. Joshua Reed2025–now

Chief operating officer

  1. David A. Broecker2006
  2. Gordon G. Pugh2007–2011
  3. Gordon G. Pugh2011–2017
  4. Blair Curtis Jackson2021–now
2010201520202025
Board members and other officers (46)

Products and brands

Alkermes has five proprietary commercial drug products approved for the treatment of narcolepsy, schizophrenia, bipolar I disorder, alcohol dependence and opioid dependence. These include sodium oxybate for extendend release oral suspension (Lumryz) olanzapine and samidorphan (Lybalvi), an atypical antipsychotic and opioid modulator combination intended for the treatment of schizophrenia and bipolar I disorder; aripiprazole lauroxil (Aristada), a long-acting injectable for schizophrenia; and naltrexone for extended-release injectable suspension (Vivitrol) for alcohol and opioid dependence.

Other products utilizing Alkermes' proprietary technologies include: diroximel fumarate (Vumerity) for multiple sclerosis, risperidone (microspheres) long-acting injectable (Risperdal Consta) for schizophrenia and bipolar I disorder, paliperidone palmitate (Invega Sustenna, Invega Trinza and Invega Hafyerain in the U.S., Xeplion, Trevicta and Bynnali in Europe) for schizophrenia.

In October 2023, Alkermes announced its first data related to its orexin 2 receptor (OXR2) agonist, alixorexton, previously known as ALKS 2680. Alixorexton is in development for the treatment of narcolepsy and idiopathic hypersomnia.

In November 2023, Alkermes completed the planned separation of its oncology business into a new company, Mural Oncology, which plans to continue to work on the investigational interleukin-2 (IL-2) drug, nemvaleukin alfa.

Read the full text

In May 2024, Alkermes completed the sale of its Athlone, Ireland facility to Novo.

In April 2025, Alkermes announced the initiation of a phase 2 study of alixorexton for the treatment of idiopathic hypersomnia.

In July 2025, Alkermes announced positive topline results from Vibrance-1, a phase 2 study evaluating alixorexton for the treatment of narcolepsy type 1.

In November 2025, Alkermes agreed to acquire sleep disorder drugmaker Avadel Pharmaceuticals for up to $2.37 billion, which includes $21 per share in cash plus $1.50 per share contingent on expanded approval of Lumryz by the end of 2028. This resulted after a bidding war between Alkermes and Danish pharmaceutical company Lundbeck. Alkermes had originally offered up to $2.1 billion, which included $18.50 per share plus the contingent $1.50. The deal closed in the first quarter of 2026.

In February 2026, CEO Richard Pops announced plans to effective August 2026. His planned replacement is Blair Jackson, Alkermes' current Chief Operating Officer.

Alkermes has multiple orexin 2 receptor agonists in development for the potential treatment of fatigue associated with multiple sclerosis and Parkinson's disease as well as attention-deficit hyperactivity disorder.

From Wikipedia’s article on Alkermes plc, shared under CC BY-SA 4.0.5

Subsidiaries and ownership

Subsidiaries

  • Alkermes (United States)

Subsidiaries (Exhibit 21)

  • Alkermes Finance Ireland (No 3) Limited Ireland6
  • Alkermes Finance LLC Delaware6
  • Alkermes Ireland Holdings Limited Ireland6
  • Alkermes Pharma Ireland Limited Ireland6
  • Alkermes Science Five Limited Ireland6
  • Alkermes Science Four Limited Ireland6
  • Alkermes US Holdings, Inc. Delaware6
  • Alkermes, Inc. Pennsylvania6
  • Avadel CNS Pharmaceuticals, LLC Delaware6
  • Avadel Finance Cayman Limited Cayman Islands6
  • Avadel Finance Ireland Designated Activity Company Ireland6
  • Avadel France Holding SAS France6
  • Avadel Investment Company Limited Cayman Islands6
  • Avadel Management, LLC Delaware6
  • Avadel Pharmaceuticals plc Ireland6
  • Avadel Research SAS France6
  • Avadel US Holdings, LLC Delaware6
  • Daravita Pharma Ireland Limited Ireland6
  • Flamel Ireland Limited Ireland6
  • Rodin Therapeutics, Inc. Delaware6

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Sep 21, 20268-K Regulation FD disclosure; Other events73
  2. Sep 16, 20268-K Executive or director change; Regulation FD disclosure74
  3. Aug 12, 20268-K Entered a material agreement75
  4. Aug 7, 2026New chief executive Blair Curtis Jackson becomes CEO16
  5. Aug 3, 20268-K Executive or director change76
  6. Jul 28, 20268-K Results of operations77
  7. Jul 8, 20268-K Ended a material agreement78
  8. Jun 15, 20268-K Regulation FD disclosure; Other events79
  9. May 20, 20268-K Executive or director change; Shareholder vote80
  10. May 12, 20268-K Regulation FD disclosure; Other events81
  11. May 5, 20268-K Results of operations82
  12. May 1, 20268-K Financial statements and exhibits83
  13. Feb 25, 20268-K Results of operations84
  14. Sep 20, 2011New chief executive Richard F. Pops becomes CEO17
  15. Jun 5, 2007New chief executive David A. Broecker becomes CEO18
  16. May 4, 2006New chief executive Richard F. Pops becomes CEO19
  17. Jul 13, 1987Founded Alkermes is founded4

Calendar

Coming up

  1. Oct 27, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.49 a share, on Oct 28, 2025.85

When it reported results

  1. Jul 28, 2026Reported quarterly or annual results77
  2. May 5, 2026Reported quarterly or annual results82
  3. Feb 25, 2026Reported quarterly or annual results84
  4. Jan 12, 2026Reported quarterly or annual results86
  5. Oct 28, 2025Reported quarterly or annual results87
  6. Oct 22, 2025Reported quarterly or annual results88
  7. Jul 29, 2025Reported quarterly or annual results89
  8. May 1, 2025Reported quarterly or annual results90

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

545 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 75 major events, 290 insider forms, 41 large holders, 117 other. The latest 20:

  1. Oct 9, 20264 PRIMARY DOCUMENT EDGAR
  2. Oct 9, 20264 PRIMARY DOCUMENT EDGAR
  3. Oct 2, 2026144 EDGAR
  4. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
  5. Sep 21, 20268-K EDGAR
  6. Sep 18, 20263 PRIMARY DOCUMENT EDGAR
  7. Sep 16, 20268-K EDGAR
  8. Sep 3, 2026144 EDGAR
  9. Sep 3, 20264 PRIMARY DOCUMENT EDGAR
  10. Sep 1, 2026144 EDGAR
  11. Sep 1, 20264 PRIMARY DOCUMENT EDGAR
  12. Aug 17, 2026144 EDGAR
  13. Aug 17, 20264 PRIMARY DOCUMENT EDGAR
  14. Aug 12, 20268-K EDGAR
  15. Aug 7, 20264 PRIMARY DOCUMENT EDGAR
  16. Aug 3, 2026144 EDGAR
  17. Aug 3, 2026144 EDGAR
  18. Aug 3, 2026144 EDGAR
  19. Aug 3, 20264 PRIMARY DOCUMENT EDGAR
  20. Aug 3, 20264 PRIMARY DOCUMENT EDGAR

The 545 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Richard F. Pops64$1.3M$7.9M100
2025Blair C. Jackson53$736.5K$4.0M100
2025Joshua Reed53$182.0K$3.8M100
2025Craig C. HopkinsonM.D.58$764.8K$3.6M100
2025David J. Gaffin54$684.5K$3.5M100
2025C. Todd Nichols57$614.9K$2.8M100
2024Chief Executive Officer and Chairman$1.2M$10.1M100
2024Executive Vice PresidentChief Operating Officer;$715.0K$4.9M100
2024Senior Vice PresidentChief Commercial Officer$597.0K$3.3M100
2023Chief Executive Officer and Chairman$1.2M$9.4M100
2023Former Interim Principal Financial Officer$650.0K$4.6M100
2023Development and Chief Medical Officer$714.0K$4.2M100
2023Chief Compliance Officer and Secretary$639.0K$4.1M100

Members of Congress who traded it

2 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Sep 29, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000+0.0%Report
Jul 30, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$15,001 - $50,000−21.7%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Alkermes is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARALKERMES INC2
  • CIK0000874663
  • Employer ID (EIN)23-24728302
  • Filer statusLarge accelerated<br>well known seasoned issuer2
  • Incorporated inPennsylvania2
  • Fiscal year endsMarch 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address852 Winter Street, Waltham, MA 02451-14202
  • Phone(781)609-60002
  • Shares outstanding97,614,842 as of Jul 25, 2011101
  • Public float$1.4B as of Jun 30, 2011101
  • On EDGAR sinceFeb 14, 19942
  • Filings987 in all: 4 (426), 8-K (132), SC 13G/A (76), 10-Q (46), 424B3 (43), SC 13G (34), CORRESP (25), 4/A (20)2
    All 53 form types

    425 (20), DEFA14A (17), S-8 (17), DEF 14A (14), 10-K (12), UPLOAD (12), 5 (10), S-3/A (10), S-3 (7), 3 (5), CT ORDER (5), SC 13D/A (5), 10-K405 (4), 8-K/A (4), 10-K/A (3), POS AM (3), SC TO-I/A (3), 10-Q/A (2), DEFR14A (2), S-1 (2), S-1/A (2), S-4/A (2), SC 13D (2), 10-C (1), 15-12B (1), 15-12G (1), 15-12G/A (1), 25-NSE (1), 3/A (1), 424B1 (1), 8-A12B (1), 8-A12G (1), 8-A12G/A (1), DEFM14A (1), DEFS14A (1), NT 10-K (1), NT 10-Q (1), PRE 14A (1), PREM14A (1), PRES14A (1), REGDEX (1), RW (1), S-1MEF (1), S-4 (1), SC TO-I (1)

  • Latest filingsAnnual report (10-K) May 20, 2011
    Quarterly report (10-Q) Aug 1, 2011
    Proxy statement (DEF 14A) Jul 29, 2010
    Latest 8-K (8-K) Sep 8, 2011

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95
  96. 96
  97. 97
  98. 98
  99. 99
  100. 100
  101. 101